Parametric Portfolio Associates’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Parametric Portfolio Associates’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,300	Closed	-$60K	–	3608
2021 Q1	$60K	Buy	2,300 +1,081	+89%	+$49.1K	﹤0.01%	4015
2020 Q4	$44K	Buy	1,219 +518	+74%	+$18.7K	﹤0.01%	3955
2020 Q3	$25K	Sell	701 -1,834	-72%	-$79.7K	﹤0.01%	3905
2020 Q2	$108K	Buy	+2,535	New	+$171K	﹤0.01%	3770
2019 Q4	–	Sell	-706	Closed	-$53K	–	4017
2019 Q3	$53K	Buy	+706	New	+$54.2K	﹤0.01%	3897

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Parametric Portfolio Associates's EVFM Position: Q2 2021 in Review

Parametric Portfolio Associates sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 2,300 shares — an estimated $60K sold.

Parametric Portfolio Associates first reported a position in EVFM in Q3 2019 and held it in 5 quarters. The position peaked at $108K in Q2 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Parametric Portfolio Associates reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Parametric Portfolio Associates sold 2,300 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $60K.
Parametric Portfolio Associates first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
Parametric Portfolio Associates's Evofem Biosciences, Inc. Common Stock position peaked at $108K in Q2 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Parametric Portfolio Associates's 13F filing for Q2 2021, filed 13 Aug 2021.